Regulatory Approval Provides Boost for Novo Nordisk Shares

Novo Nordisk DK0062498333

European regulators have granted a significant approval to Novo Nordisk, offering the Danish pharmaceutical giant timely positive news. The European Commission has authorized a higher 7.2 mg maintenance dose for the weight-loss medication Wegovy (semaglutide), with the decision dated February 17, 2026. This endorsement provides the company with an enhanced competitive position in the high-stakes obesity treatment market, following a severe decline in its share price earlier in the month.

This regulatory win arrives at a pivotal moment for Novo Nordisk. On February 4, the company's stock plummeted between 15 and 18 percent after management issued a disappointing financial outlook for 2026. The forecast anticipates a decline in both revenue and operating profit for the full year, projected to be in the range of 5 to 13 percent.

Company leadership cited lower realized prices in the United States as a primary driver, resulting from government price negotiations and fierce competition with rival Eli Lilly. The U.S. competitor has captured significant market share with its own GLP-1 products and is projecting robust growth for the same period. Currently, Novo Nordisk shares are trading on the NYSE in the $49 to $50 range, well below their 52-week highs.

Study Data Underpins EU Decision

The Commission's approval, valid across all 27 member states, applies to adult patients with obesity. The authorization is based on findings from the STEP-UP study, which involved 1,407 participants. Data showed that after 72 weeks of treatment, patients on the 7.2 mg dose lost an average of approximately 21 percent of their body weight.

This represents an improvement over the previously approved 2.4 mg dose, which demonstrated an average weight reduction of 17.5 percent in earlier trials. A notable finding was that about one-third of participants receiving the higher dosage lost at least 25 percent of their body weight. Until a dedicated single-dose pen becomes available?potentially later in 2026?physicians can prescribe the new dosage as three simultaneous 2.4 mg injections.

Corporate Response: Buybacks and Litigation

In response to market pressures, Novo Nordisk has initiated strategic countermeasures. A share repurchase program of up to 15 billion Danish kroner commenced on February 4, set to run for twelve months. Concurrently, the firm is pursuing legal action against companies such as Hims & Hers, which sell compounded versions of semaglutide, citing significant patient safety concerns.

Analyst perspectives on the stock remain divided. Barclays recently lowered its price target, referencing the weak annual guidance. Conversely, Jefferies upgraded its rating on the shares to "Hold" on February 12, arguing that the current valuation already reflects much of the negative outlook.